Clinical correlates of depressive symptoms in familial Parkinson's disease

Autor: Nathan Pankratz, Alice Rudolph, Cliff Shults, Tatiana Foroud, Cheryl A. Halter, Karen Marder, William C. Nichols

Publikováno v: Movement Disorders. 23:2216-2223

Depression is one of the most common nonmotor complications of Parkinson's disease (PD) and has a major impact on quality of life. Although several clinical factors have been associated with depression in PD, the relationship between depression and s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c0487dbe8f7d7a87c1aaf14fafc28de6
https://doi.org/10.1002/mds.22285

Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease

Autor: Francis O. Walker, Juliette Harris, Holly Delgado, David Simon, Paul J. Tuite, Jayaraman Rao, Kelly E. Lyons, Tilak Mendis, Bala V. Manyam, Joanna Hamman, Deborah Fontaine, Terry Reed, William C. Nichols, Sharon Evans, Joanne Wojcieszek, Peggy Gray, Anette Nieves, Carson Reider, P. Michael Conneally, W.R. Wayne Martin, Kathy Davis, Christine Hunter, Daniel D. Truong, John M. Bertoni, Hubert H. Fernandez, Joseph H. Friedman, Nathan Pankratz, Margaret C. Lannon, Kenneth Marek, Maryan DeAngelis, Mark Stacy, Debra Berry, Mariann DiMinno, Robyn Schacherer, Becky Dunlop, Michel Panisset, Carmen Serrano Ramos, Alice Rudolph, Tatiana Foroud, Theresa A. Zesiewicz, David Grimes, An Tran, Joan Werner, Jean Hall, Sandra Roque, Magali Fernandez, Joseph Jankovic, Michael J. Aminoff, Rachel Saunders Pullman, Maureen A. Leehey, Cliff Shults, Deborah Judd, William C. Koller, Mark Forrest Gordon, Cheryl Halter, Ali H. Rajput, Pam Andrews, Stephen G. Reich, Theresa Derian, Alex Rajput, Stephanie Thomas, Galit Kleimer-Fisman, Susan Mendick, Robert A. Hauser, Danna Jennings, Paul Gordon, Stewart A. Factor, Peter A. LeWitt, Un Jung Kang, Karyn Boyar, Ronald F. Pfeiffer, Robert L. Rodnitzky, Jean P. Hubble, Jeannine Petit, Mayank Pathak, Julie H. Carter, Maureen Cook, William J. Weiner, Rajesh Pahwa, Christopher F. O'Brien, Karen Marder, Joan Young, Judith Dobson, Richard Camicioli, Lawrence Elmer, Jo Belden, Julie So, Theresa Shirley, Anthony E. Lang, Roger Kurlan, Kelli Williamson, Brenda Pfeiffer, Victoria Hunt, Sean K. Uniacke, Clifford W. Shults, Karen Blindauer, Lauren Seeberger, Brian Wulbrecht, Carolyn Peterson

Publikováno v: Movement Disorders. 19:649-655

Parkinson's disease (PD) is a common neurodegenerative disorder in humans with wide variability in the age of disease onset. Although the disease has been thought previously to occur sporadically in most patients, there is increasing evidence of a ge

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7de9a5b2e01f1af7dbb8612a83c762b
https://doi.org/10.1002/mds.20097

R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation

Autor: Karen Williams, Carolyn Peterson, S. Narayan, Margaret F. Turk, Julie H. Carter, C. Schell, Carlos Singer, Chad W. Christine, Paul J. Tuite, Robyn Schacherer, J. Whetteckey, S. Phipps, Diane K. Marek, William C. Nichols, John M. Bertoni, A. H. Rajput, Kenneth Marek, An Tran, P. Ryan, J. Hevezi, Joan Werner, Kelvin L. Chou, S. Chouinard, James Sutton, Margaret C. Lannon, T. Ajax, Joan Young, Deborah Judd, L. Zelaya, David Grimes, Magali Fernandez, Theresa A. Zesiewicz, Mark Stacy, Peggy Gray, Debra Berry, Michael J. Aminoff, C. Horn, C. Costan-Toth, J. Mannetter, Patricia Simpson, Susan Rolandelli, Tatiana Foroud, T. Tra, S. Wilson, Judith Dobson, Nestor Galvez-Jimenez, Donna Schwieterman, Shirley Uy, K. Price, J. Wojcieszek, Anette Nieves, Paul Atchison, Susan Bennett, L. Klassen, A. Podichetty, Vincent Calabrese, Becky Dunlop, D. Kamp, Holly Delgado, Sandra Roque, Maureen A. Leehey, Richard Camicioli, Julie So, Jayaraman Rao, Kelly E. Lyons, Kapil D. Sethi, A. Wang, Lynn Marlor, David Oakes, S. Culver, Juan Sanchez-Ramos, L. Woodward, J. Danielson, Jeannine Petit, Joann Belden, E. Licari, M. Meacham, Deborah Fontaine, Sharon Evans, C. Stone, S. Morehouse, Christopher F. O'Brien, G. Podskalny, J. Fraser, Anthony E. Lang, W.R. Wayne Martin, Carmen Serrano, H. Poiffaut, Stewart A. Factor, Joanne Wojcieszek, S. Belber, L. Davis, C. Allen, J. Hall, Judy Richman, Joseph Jankovic, Carson Reider, Stephen G. Reich, Stephanie Thomas, Kathy Davis, Richard B. Dewey, Karen Marder, T. Demarcaida, A. Kaczmarek, Lauren Seeberger, C. Halter, Mary Lou Klimek, Donald S. Higgins, Miodrag Velickovic, Joanna Hamann, Eric Siemers, E. Ohmann, C. Dingmann, Galit Kleiner-Fisman, Shari Niswonger, Theresa Derian, Maryan DeAngelis, Aileen Shinaman, Tilak Mendis, M. Rundle, Susan Mendick, L. Giffin, Karen Blindauer, Paul Gordon, Andrew Feigin, L. Shulman, Maureen Cook, Brian Wulbrecht, Rajesh Pahwa, T. Foroud, Un Jung Kang, Arthur Watts, Oksana Suchowersky, C. Joubert, J. Vo, Mandar Jog, M. Panisset, Roberta Winnick, Ronald F. Pfeiffer, Barbara Shannon, Jean P. Hubble, Clifford W. Shults, T. Gales, Tanya Simuni, M. Wolff, Hubert H. Fernandez, Pam Andrews, Karyn Boyar, Brad A. Racette, Vicki Hunt, Christine Hunter, Daniel D. Truong, L. Good, Robert L. Rodnitzky, P. Rodriguez, Sandra K. Kostyk, T. Shirley, Cheryl Halter, Peter A LeWitt, W. Weiner, Ryan J. Uitti, Lisa Scollins, Marc L. Gordon, J. Carpenter, Alice Rudolph, Lewis Sudarsky, Robert A. Hauser, Cliff Shults, Bala V. Manyam, Francis O. Walker, Juliette Harris, Marguerite Wieler, K. Dustin, Kelli Williamson, Brenda Pfeiffer, William C. Koller, Frederick J. Marshall, V. Hagen, A. Campbell, B. Hutchinson, L. Elmer, Anja Rudolph, K. Haas, Tori Ross, Rachel Saunders-Pullman, Nathan Pankratz, E. Aiken, Mariann DiMinno, Peggy Roberge, Arif Dalvi, B. Hayward, Mayank Pathak, David Simon, Michael W. Pauciulo, Holly A. Shill, M. Marotta-Kollarus, K. Ligon, Alok Sahay, Joseph H. Friedman, Neal Hermanowicz, E. Julian-Baros, Irenita Gardiner, N. Luong, Danna Jennings, R. Kurlan, P. M. Conneally

Publikováno v: Movement Disorders. 22:254-256

Mutations in LRRK2 were first reported as causing Parkinson's disease (PD) in late 2004. Since then, approximately a dozen LRRK2 substitutions have been identified that are believed to be pathogenic mutations. The substitution of adenine for guanine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c48f0117672933936e1f3bb8ac731d4
https://doi.org/10.1002/mds.21233

Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease

Autor: Arthur Watts, Blair Ford, Marsha Tennis, Ronald F. Pfeiffer, Jean P. Hubble, Cliff Shults, Mickie Welsh, John Seibyl, Carolyn Weeks, Sandra Dillon, John P. Hammerstad, Amy Montgomery, Stewart A. Factor, Farah Atassi, William J. Weiner, Barbara Alexander-Brown, Karl Kieburtz, Roger Kurlan, David S. Russell, Stanley Fahn, Ali H. Rajput, Jean Hall, Ira Shoulson, Brenda Pfeiffer, Bruno Musch, Karen Richard, Deborah Fontaine, David G. Standaert, Kevin M. Biglan, Mark Stacy, Debra Berry, Frederick Wooten, Diane Brown, Michael P. McDermott, Tori Ross, Giselle Petsinger, Theresa Shirley, Susan E. Bennett, Leona Borchert, Kenneth Marek, Laura Sutherland, Rajesh Pahwa, Janis M. Miyasaki, Susan Wood, Robert G. Holloway, Cornelia Kamp, Sharon Evans, Pamela Rainey, Anthony E. Lang, Michel Panisset, Elspeth Sime, Carol Pantella, Susan Daigneault, Barbara Fussell, Carolynn O'Connell, Joseph Jankovic, Aileen Shinaman, Elke Rost-Ruffner, Peter A. LeWitt, Alicia Brocht, Karen Hodgeman, Cheryl Waters, Mary Harrigan, Robert L. Rodnitzky, Judith Dobson, David E. Riley, Oksana Suchowersky, Maryan DeAngelis, Lynn Barclay

Publikováno v: Archives of Neurology. 61

BACKGROUND The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear. OBJECTIVE To compare initial treatment with pramipexole vs levodopa in early Parkinson disease, followed by levodopa supplementation, with respect t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::416eb9465f792702da6023996d72d71f
https://doi.org/10.1001/archneur.61.7.1044

A developmental influence of substance P on its receptors

Autor: Gail E. Handelmann, Cliff Shults, Thomas L. O'Donohue

Publikováno v: International Journal of Developmental Neuroscience. 5:11-15

Events which alter the chemical environment of the developing nervous system have long-term consequences for neural function and behavior. Neonatal exposure to a peptide neurotransmitter, substance P (SP), increased the number of SP binding sites in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::818534f8f61cfc47ad1f358da734d4e5
https://doi.org/10.1016/0736-5748(87)90043-8